Multipurpose prevention technologies (MPTs) are designed to target HIV prevention as well as an additional indication such as preventing unintended pregnancies or transmission of other sexually transmissible infections (STIs) such as herpes simplex virus (HSV) infection. Delivery strategies under development include sustained release IVRs (27). While a ring with additional indications, such as preventing pregnancy, may increase uptake by reducing stigma normally associated with the use of specific HIV prevention modalities, MPTs manufacture is likely to be expensive and obtaining regulatory approval will be challenging due to the presence of two or more active pharmaceutical ingredients (27). Please refer to the AVAC website for more information in MPTs (https://www.avac.org/prevention-option/multipurpose-prevention-technologies).
- Epidemiology & Natural History
- Virology & Immunology
- Diagnostic & Monitoring Tests
- Primary HIV infection
- HIV-infectious Disease & Cancer
- Respiratory tract infections in patients with HIV infection
- Tuberculosis
- Non-tuberculous mycobacterial infections in people with HIV infection
- Opportunistic infections of the gastrointestinal tract
- Ocular disease in patients with HIV infection
- Opportunistic infections acquired in localised geographical regions of the world
- Human papillomavirus-associated malignancy
- Skin disease
- Opportunistic infections of the nervous system (coming soon)
- Malignant and lymphoproliferative conditions complicating HIV infection (coming soon)
- Opportunistic infections and cancers of the mouth and oropharynx (coming soon)
- Other HIV-Associated Disease
- Co-infections
- ARV Drugs & other Therapies
- Antiretroviral drugs
- Initiation of antiretroviral therapy in treatment-naïve people
- Long-term management of antiretroviral therapy
- Antiretroviral therapy guidelines
- Immune reconstitution inflammatory syndrome and other immune reconstitution disorders
- Prevention of opportunistic infections with antimicrobial therapy (coming soon)
- Drug-drug interactions in patients with HIV infection
- Adverse reactions to antiretroviral and other drugs in people with HIV infection
- Vaccines in people with HIV infection
- Co-Morbidities
- Special Patient Populations
- Biomedical prevention
- Nurses & Midwives
- New HIV Diagnosis
- Late presentation of new HIV diagnosis
- Partner notification and contact tracing
- Key Affected Populations
- Pregnancy and midwifery considerations in HIV
- Paediatric issues
- Client education
- Nursing considerations of major clinical issues
- HIV-associated neurocognitive disorder
- Adherence support
- Health promotion
- Clinical supervision for nurses in the HIV sector
- Biomedical HIV prevention
- Evolving roles of nurses in HIV care
- Nursing ethics in the care of people with HIV
